April 20, 2016


Second Genome Raises $42.6M Series B to Pursue Microbiome-Based Therapies

By Brian Gormley

Second Genome Inc. has attracted the venture arms of two drug companies to a $42.6 million financing that will enable it to develop disease treatments based on research into the population of microbes that live in and on the body.

New investors Pfizer Venture Investments and Roche Venture Fund led the Series B round, which also included new backers Adveq, Digitalis Ventures, LifeForce Capital and MBL Venture Group....

To read more: http://pevc.dowjones.com/Article?an=DJFVW00120160420ec4kb300x&cid=&ctype=&from=Search&ReturnUrl=http%3a%2f%2fpevc.dowjones.com%2fArticle%3fan%3dDJFVW00120160420ec4kb300x%26cid%3d%26ctype%3d%26from%3dSearch